All Stories

  1. Muscarinic Receptor Activators—What Is Their Place in Clinical Care?

    Article • JAMA Psychiatry, December 2025, American Medical Association (AMA)

    Associate professor Mikkel Højlund

  2. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis

    Article • European Neuropsychopharmacology, December 2025, Elsevier

    Associate professor Mikkel Højlund

  3. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making

    Article • BMJ, November 2025, BMJ

    Associate professor Mikkel Højlund

  4. Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: Prevalence, time trends, and combinations

    Article • European Neuropsychopharmacology, November 2025, Elsevier

    Associate professor Mikkel Højlund

  5. Psychotropic Drug Use Among Danish Care Home Residents During and After the COVID ‐19 Pandemic

    Article • Journal of the American Geriatrics Society, October 2025, Wiley

    Associate professor Mikkel Højlund

  6. Efficacy and Acceptability of Licensed and Off‐Label Pharmacological Interventions for Insomnia in Patients With Severe Mental Illness: A Systematic Review and Meta‐Analysis of Randomised Trials

    Article • Acta Psychiatrica Scandinavica, September 2025, Wiley

    Associate professor Mikkel Højlund

  7. Switching to a muscarinic agonist to alleviate antipsychotic-induced metabolic and neuromotor adverse effects in a person living with schizophrenia

    Article • Journal of Psychiatry and Neuroscience, August 2025, Canadian Science Publishing

    Associate professor Mikkel Højlund

  8. From Idealist to Realist—Designing and Implementing Shared Decision-Making Interventions in the Choice of Antipsychotic Prescription in People Living with Psychosis (SHAPE): A Realist Review

    Article • Schizophrenia Bulletin, May 2025, Oxford University Press (OUP)

    Associate professor Mikkel Højlund

  9. From Idealist to Realist—Designing and Implementing Shared Decision-Making Interventions in the Choice of Antipsychotic Prescription in People Living With Psychosis (SHAPE): A Realist Review (Part 2—Designing SDM Interventions: Optimizing Design and Lo...

    Article • Schizophrenia Bulletin, May 2025, Oxford University Press (OUP)

    Associate professor Mikkel Højlund

  10. On the potential of xanomeline-trospium chloride for schizophrenia and beyond

    Article • European Neuropsychopharmacology, May 2025, Elsevier

    Associate professor Mikkel Højlund

  11. Comparative efficacy and acceptability of interventions for universal, selective and indicated prevention of eating disorders: study protocol for a systematic review and network meta-analysis

    Article • Journal of Eating Disorders, April 2025, Springer Science + Business Media

    Associate professor Mikkel Højlund

  12. Medical consultation to identify somatic disorders and abnormal paraclinical findings in hospitalized psychiatric patients is feasible and worthwhile

    Article • Nordic Journal of Psychiatry, March 2025, Taylor & Francis

    Associate professor Mikkel Højlund

  13. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis

    Article • European Neuropsychopharmacology, March 2025, Elsevier

    Associate professor Mikkel Højlund

  14. Initiation and Discontinuation of Psychotropic Drugs Relative to Suicidal Behavior: A Danish Registry‐Based Study

    Article • Acta Psychiatrica Scandinavica, February 2025, Wiley

    Associate professor Mikkel Højlund

  15. Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia

    Article • European Neuropsychopharmacology, February 2025, Elsevier

    Professor Jari Tiihonen, Associate professor Mikkel Højlund

  16. Excess cardiometabolic risk in children and adolescents initiating antipsychotic treatment compared to young adults: results from a nationwide cohort study

    Article • World Psychiatry, January 2025, Wiley

    Associate professor Mikkel Højlund

  17. Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis

    Article • The Lancet Psychiatry, December 2024, Elsevier

    Associate professor Mikkel Højlund

  18. The risk of diabetes and HbA1c deterioration during antipsychotic drug treatment: A Danish two‐cohort study among patients with first‐episode schizoph...

    Article • Acta Psychiatrica Scandinavica, October 2024, Wiley

    Associate professor Mikkel Højlund

  19. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review

    Article • Expert Opinion on Drug Safety, September 2024, Taylor & Francis

    Associate professor Mikkel Højlund

  20. Efficacy and acceptability of interventions to reduce antipsychotic polypharmacy: A systematic review and meta-analysis of randomized clinical trials

    Article • Schizophrenia Research, August 2024, Elsevier

    Associate professor Mikkel Højlund

  21. The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment

    Article • The World Journal of Biological Psychiatry, June 2024, Taylor & Francis

    M.D., resident in Psychiatry Renato de Filippis, Associate professor Mikkel Højlund

  22. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review

    Article • Current Neuropharmacology, May 2024, Bentham Science Publishers

    Associate professor Mikkel Højlund, Angelina Isabella Mellentin

  23. Outcomes in people with eating disorders: a transdiagnostic and disorder‐specific systematic review, meta‐analysis and multivariable meta‐regression analysis

    Article • World Psychiatry, January 2024, Wiley

    Associate professor Mikkel Højlund

  24. Smoking and severe mental illness: Drawing inference on the directionality of the association requires careful consideration of the temporality of the data

    Article • Acta Psychiatrica Scandinavica, November 2023, Wiley

    Associate professor Mikkel Højlund

  25. An umbrella review of candidate predictors of response, remission, recovery, and relapse across mental disorders

    Article • Molecular Psychiatry, September 2023, Springer Science + Business Media

    Associate professor Mikkel Højlund

  26. Neonatal and maternal outcomes with elective cesarean section compared to induction of labor in twin pregnancies: A prospective cohort study

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, July 2023, Elsevier

    Associate professor Mikkel Højlund

  27. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches

    Article • Expert Opinion on Pharmacotherapy, June 2023, Taylor & Francis

    Associate professor Mikkel Højlund

  28. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis

    Article • The International Journal of Neuropsychopharmacology, June 2023, Oxford University Press (OUP)

    Associate professor Mikkel Højlund

  29. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Article • Neuroscience & Biobehavioral Reviews, June 2023, Elsevier

    Associate professor Mikkel Højlund, Dr Edna Grünblatt, Dejan Stevanovic

  30. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

    Article • World Psychiatry, January 2023, Wiley

    Associate professor Mikkel Højlund

  31. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

    Article • World Psychiatry, January 2023, Wiley

    Associate professor Mikkel Højlund

  32. Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events

    Article • Acta Neuropsychiatrica, January 2023, Cambridge University Press

    Associate professor Mikkel Højlund

  33. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia

    Article • Expert Opinion on Investigational Drugs, December 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  34. Use of benzodiazepines and benzodiazepine‐related drugs in the Nordic countries between 2000 and 2020

    Article • Basic & Clinical Pharmacology & Toxicology, November 2022, Wiley

    Associate professor Mikkel Højlund

  35. Impact of low‐dose quetiapine‐use on glycosylated hemoglobin, triglyceride and cholesterol levels

    Article • Acta Psychiatrica Scandinavica, November 2022, Wiley

    Associate professor Mikkel Højlund

  36. Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study

    Article • World Psychiatry, September 2022, Wiley

    Associate professor Mikkel Højlund

  37. Free‐of‐charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications

    Article • Basic & Clinical Pharmacology & Toxicology, August 2022, Wiley

    Associate professor Mikkel Højlund

  38. Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study

    Article • Schizophrenia Research, August 2022, Elsevier

    Associate professor Mikkel Højlund

  39. Lithium and the risk of chronic kidney disease: A population‐based case–control study

    Article • Basic & Clinical Pharmacology & Toxicology, June 2022, Wiley

    Associate professor Mikkel Højlund

  40. Hospitalization time is associated with weight gain in forensic mental health patients

    Article • European Psychiatry, June 2022, Royal College of Psychiatrists

    Associate professor Mikkel Højlund

  41. Who prescribes quetiapine in Denmark?

    Article • British Journal of Clinical Pharmacology, May 2022, Wiley

    Associate professor Mikkel Højlund

  42. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study

    Article • BMJ, April 2022, BMJ

    Associate professor Mikkel Højlund

  43. Hospitalisation time is associated with weight gain in forensic mental health patients with schizophrenia or bipolar disorder

    Article • Nordic Journal of Psychiatry, April 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  44. Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions

    Article • Clinical Epidemiology, April 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  45. Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

    Article • Basic & Clinical Pharmacology & Toxicology, February 2022, Wiley

    Associate professor Mikkel Højlund

  46. Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia

    Article • JAMA Psychiatry, January 2022, American Medical Association (AMA)

    Associate professor Mikkel Højlund

  47. RE : Gout and sodium‐glucose cotransporter‐2 inhibitors

    Article • Pharmacoepidemiology and Drug Safety, November 2021, Wiley

    Associate professor Mikkel Højlund

  48. Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis

    Article • Thorax, September 2021, BMJ

    Associate professor Mikkel Højlund, Mikkel Brabrand

  49. Lung ultrasound to phenotype chronic lung allograft dysfunction in lung transplant recipients. A prospective observational study

    Article • September 2021, European Respiratory Society (ERS)

    Jesper Rømhild Davidsen, Associate professor Mikkel Højlund, Dr Michael Perch

  50. Diagnostic accuracy of focused deep venous, lung, cardiac, and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis

    Article • September 2021, European Respiratory Society (ERS)

    Associate professor Mikkel Højlund, Mikkel Brabrand

  51. Withdrawal-associated relapse is a potential source of bias – Authors' reply

    Article • The Lancet Psychiatry, September 2021, Elsevier

    Associate professor Mikkel Højlund

  52. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials

    Article • The Lancet Psychiatry, June 2021, Elsevier

    Associate professor Mikkel Højlund

  53. Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis

    Article • Pharmacoepidemiology and Drug Safety, May 2021, Wiley

    Associate professor Mikkel Højlund

  54. Association of Low-Dose Quetiapine and Diabetes

    Article • JAMA Network Open, May 2021, American Medical Association (AMA)

    Associate professor Mikkel Højlund

  55. How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block

    Article • Journal of Clinical Psychopharmacology, April 2021, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  56. Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study

    Article • Journal of Clinical Medicine, March 2021, MDPI AG

    Associate professor Mikkel Højlund, Dr Michael Perch

  57. Use of antipsychotics in Denmark 1997–2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses

    Article • Epidemiology and Psychiatric Sciences, January 2021, Cambridge University Press

    Associate professor Mikkel Højlund

  58. Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study

    Article • BMJ Open, August 2020, BMJ

    Associate professor Mikkel Højlund

  59. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016

    Article • British Journal of Clinical Pharmacology, May 2019, Wiley

    Associate professor Mikkel Højlund

  60. Effect of a 30-Month Health-Promoting Program on the Prevalence of Cardiovascular Risk Factors in Patients With First Episode Schizophrenia

    Article • American Journal of Therapeutics, January 2019, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  61. Obstructive hydrocephalus caused by colloid cyst presenting as a schizophrenia-like psychosis

    Article • BMJ Case Reports, June 2018, BMJ

    Associate professor Mikkel Højlund

  62. Does the use of medication go up, when the use of restraint go down?

    Article • International Journal of Social Psychiatry, February 2018, SAGE Publications

    Associate professor Mikkel Højlund

  63. Differences in Antipsychotic Prescriptions Between Centers in Young Outpatients With Schizophrenia

    Article • Journal of Clinical Psychopharmacology, December 2017, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  64. Does life-style intervention lower the need for antipsychotics in ypung people with schizophrenia?

    Article • Nordic Journal of Psychiatry, August 2017, Taylor & Francis

    Associate professor Mikkel Højlund

  65. QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy

    Article • CNS Spectrums, June 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  66. Does the Use of Psychotropic Medication go up During Focused Efforts to Bring Coercion and Restraint Down?

    Article • European Psychiatry, April 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  67. Decrease in antipsychotic and other psychotropic medication during 30 months of lifestyle intervention among outpatients with schizophrenia

    Article • European Psychiatry, April 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  68. QTc Interval in individuals with schizophrenia receiving antipsychotic as monotherapy or polypharmacy

    Article • European Psychiatry, April 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  69. Life-threatening effects of antipsychotic drugs (1st edition)

    Article • Nordic Journal of Psychiatry, March 2017, Taylor & Francis

    Associate professor Mikkel Højlund